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Abstract: The treatment of presbyopia has been the focus of much scientific and clinical 
research over recent years, not least due to an increasingly aging population but also the desire 
for spectacle independence. Many lens and nonlens-based approaches have been investigated, 
and with advances in biomaterials and improved surgical methods, removable corneal inlays 
have been developed. One such development is the KAMRA™ inlay where a small entrance 
pupil is exploited to create a pinhole-type effect that increases the depth of focus and enables 
improvement in near visual acuity. Short- and long-term clinical studies have all reported 
significant improvement in near and intermediate vision compared to preoperative measures 
following monocular implantation (nondominant eye), with a large proportion of patients 
achieving Jaeger (J) 2 to J1 (~0.00 logMAR to ~0.10 logMAR) at the final follow-up. Although 
distance acuity is reduced slightly in the treated eye, binocular visual acuity and function 
remain very good (mean 0.10 logMAR or better). The safety of the inlay is well established 
and easily removable, and although some patients have developed corneal changes, these are 
clinically insignificant and the incidence appears to reduce markedly with advancements in 
KAMRA design, implantation technique, and femtosecond laser technology. This review aims 
to summarize the currently published peer-reviewed studies on the safety and efficacy of the 
KAMRA inlay and discusses the surgical and clinical outcomes with respect to the patient’s 
visual function.
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Introduction
Treatment for the correction of presbyopia has continued to be the focus of considerable 
research. Typically affecting people from 40 years of age, the loss of near visual acuity 
is often attributed to increased lens nucleus hardness and subsequent inability of the 
lens capsule to compress the lens to a more convex state over time.1–3 However, as lens 
thickness increases with age, the space between the lens and ciliary body reduces, and 
the angle of zonule insertion may change and therefore render ciliary body contraction 
ineffective.4–6 Presbyopia can significantly impact the quality of life and combined 
with an increasingly aging global population it poses a greater demand for spectacle 
independence.7
Approaches to treat presbyopia have included the use of intracorneal inlays to either 
change the refractive power of the cornea based on corneal multifocality8 or increase 
the refractive power of the central cornea by changing its curvature.9,10 Another inlay 
method which has been studied in great detail is the use of small-aperture optics to 
increase the depth of focus based on the pinhole effect.11,12 This commercially avail-
able inlay is known as the KAMRA™ inlay (AcuFocus Inc., Irvine, CA, USA), and 
this review aims to summarize the efficacy and safety of currently published clinical 
studies of this procedure.
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Methodology
Clinical trials of the KAMRA inlay used in this literature 
review were searched in PubMed using the following 
keywords alone and in combination (where appropriate): 
KAMRA, corneal inlay, safety, efficacy, and visual outcomes. 
In total, 14 clinical trials were identified and used for 
analysis.
The KAMRA inlay
The KAMRA design (ACI7000PDT) consists of a 3.8 mm 
diameter microperforated (8,400 holes 5–11 µm in diameter) 
tinted disc with 1.6 mm central aperture at 6 µm thick and is 
made of polyvinylidene fluoride and carbon nanoparticles. 
Figure 1 shows the size of the KAMRA inlay compared to a 
14 mm soft contact lens. The inlay is designed to be inserted 
in the line if sight of the nondominant eye and implanted in 
a femtolaser created corneal lamellar pocket at least 220 µm 
deep. Figure 2 shows a schematic of the inlay design.
The inlay is designed to allow light to enter through the 
central aperture, thus reducing retinal image blur and increas-
ing depth of focus to allow increased near and intermediate 
visual acuity. As the inlay does not split light between 
different focal points, this allows the patient to maintain 
binocular summation.13 Figure 3 shows the inlay in situ in 
a patient’s cornea.
Given that this is an additive procedure (ie, no corneal 
tissue is removed), it can be combined with refractive laser 
vision correction procedures where the eyes are made 
emmetropic – here the inlay is situated in a lamellar pocket 
at least 100 µm beneath the initial laser in situ keratomileusis 
(LASIK) flap.14 Further, it can be implanted in previously 
pseudophakic eyes, which has been shown, albeit in a few 
cases, to produce a significant improvement in near acuity 
without affecting distance acuity.15 Based on an eye model, 
it has been suggested that the best depth of focus is achieved 
where the dominant eye is made plano and the nondominant 
eye is made myopic (-0.75 to -1.00 D).16
Clinical performance
The efficacy of the KAMRA inlay has been investigated in 
several studies, albeit in case series where pre- and postopera-
tive measures were compared rather than case-control clinical 
studies. Nonetheless, all have reported significant improve-
ments in near visual acuity following implantation. However, 
it should be borne in mind by the reader that all currently 
published studies are company sponsored (AcuFocus).
In a study comprising hyperopic, myopic, and emme-
tropic patients (180 patients), the KAMRA inlay (model 
ACI7000PDT) was implanted in the nondominant eye 
together with a bilateral LASIK for the ametropic patients. 
Although only 64 patients were available for follow-up, 
the KAMRA-treated eye resulted in a seven-line improve-
ment in logMAR uncorrected near visual acuity (UNVA) 
in hyperopic eyes (to mean of 0.18 logMAR), two lines 
in myopic eyes (0.12 logMAR), and six lines in emme-
tropic eyes (0.10 logMAR) after 6 months.14 The smaller 
Figure 1 The size of the KAMRA inlay compared to a 14 mm diameter soft contact lens.
Figure 2 A schematic of the KAMRA inlay design.
Figure 3 The KAMRA inlay inserted in a patient’s cornea.
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improvement in myopic eyes was not unexpected due to 
preoperative good UNVA, and this was reflected in the 
patient satisfaction scores for this myopic group where 
the improvement in overall vision was not statistically 
significant.14 Uncorrected distance visual acuity (UDVA 
[logMAR]) also improved in the treated eye, by three lines 
in hyperopic eyes (to mean of -0.04 logMAR), ten lines in 
myopic eyes (-0.01 logMAR), and one line in emmetropic 
eyes (-0.07 logMAR) – again the smaller improvements 
were not unexpected in the emmetropic and hyperopic eyes.14 
Although there were significant differences in UNVA and 
UDVA between each group preoperatively, no significant 
differences were observed 6 months after implantation; thus, 
the KAMRA inlay can be implanted after a LASIK procedure 
and the postoperative results appear similarly successful 
despite preoperative ametropia.14
Another case series by the same study group investi-
gated the visual outcomes of the KAMRA inlay (model 
ACI7000PDT; again implanted in the nondominant eye) in 
223 presbyopic patients who had previously undergone LASIK 
refractive surgery for emmetropia (mean spherical equivalent 
of -0.18 D in treated eye). After 6 months, the mean UNVA 
improved from Jaeger (J) 8 (~0.50 logMAR) to J2 (~0.10 
logMAR) in the treated eye, but unfortunately binocular 
UNVA (BUNVA) was not reported.17 However, despite mean 
UDVA reducing slightly by one line from -0.10 logMAR to 
0.00 logMAR in the treated eye, the mean binocular UDVA 
(BUDVA) remained very good (-0.20 logMAR).17 Although 
29% of patients had .0.50 D change, with a slight myopic 
shift compared to baseline, mean spherical equivalent refrac-
tion remained stable.17 Patient satisfaction of their visual status 
(1= least, 7= most satisfied) without reading glasses under 
bright light conditions improved significantly compared to 
baseline for all near (reading newspaper: 3.3±2.1 to 5.0±1.4; 
reading stock price on medicine bottle: 1.5±1.1 to 4.1±1.8) 
and intermediate tasks (reading the computer screen: 2.8±1.7 
to 5.6±1.2) examined.17
Two-year follow-up of the efficacy of this inlay has 
also been investigated in 24 emmetropic presbyopes who 
underwent monocular implantation in the nondominant eye. 
In this study, the mean UNVA improved from 0.40 logMAR 
to 0.10 logMAR in the treated eye, with 83% achieving 0.10 
logMAR or better.18 Mean unaided intermediate visual acuity 
(UIVA) improved from 0.20 logMAR to 0.10 logMAR, but 
UDVA decreased by one line compared to baseline in the 
treated eye (-0.10 logMAR to 0.00 logMAR). However, this 
is considered very good acuity and BUDVA remained stable 
(-0.10 logMAR over the 2-year period).18
Longer-term studies have also been reported, but 
mainly with the previous (original) version of the KAMRA 
implant (model ACI7000). This implant is slightly thicker 
(10 µm) than the current design and has fewer porosity holes 
(1,600 holes 25 µm in diameter). In a prospective cohort 
study, 32 naturally emmetropic patients who underwent 
implantation in the nondominant eye achieved mean UNVA 
of J2 (~0.10 logMAR) after 2 years in the treated eye com-
pared to J7/J8 (~0.48/0.50 logMAR) preoperatively, with 
96.9% of patients reading J3 (~0.18 logMAR) or better.19 
Mean BUNVA also improved significantly from J6 (~0.40 
logMAR) preoperatively to J1 (~0.00 logMAR). Mean 
UIVA improved from 0.30 logMAR to 0.10 logMAR in 
the treated eye and from 0.20 logMAR to 0.00 logMAR 
binocularly, with 71.9% of patients achieving 0.00 logMAR 
or better.19 Although there was no significant difference 
between preoperative (-0.10 logMAR) and postoperative 
(-0.10 logMAR) BUDVA, six patients experienced a reduc-
tion to 0.10 logMAR and two patients to 0.20 logMAR.19 
However, mean UDVA in the treated eye remained 
0.00 logMAR over the 2-year follow-up period.19 The same 
study group also reported at 3 years postoperatively on the 
same patient cohort. Mean UNVA was J1 (~0.00 logMAR), 
UIVA was 0.10 logMAR, and UDVA was 0.00 logMAR in 
the treated eye.20
Yılmaz et al investigated the efficacy of the original inlay 
design up to 4 years postoperatively (n=22 patients) in the 
natural and post-LASIK (to correct hyperopia) emmetropic 
presbyopes.21 Here, UNVA improved significantly from 
J7 (0.40 logMAR) preoperatively to J1 (0.00 logMAR) in the 
treated eye (mean improvement of 3.8±1.5 lines; 96% reading 
J3 [~0.18 logMAR] or better) at the last study visit. Compared 
to baseline, UDVA decreased, albeit statistically insignifi-
cantly, by one line (0.00 logMAR to 0.10 logMAR) in the 
treated eye over the 4-year period.21 The longest follow-up 
with the KAMRA inlay (ACI7000) was recently reported 
by Dexl et al, where it was implanted in the nondominant 
eye of 32 natural emmetropic presbyopes.22 Mean UNVA 
improved significantly from J7/J8 (~0.50 logMAR) preop-
eratively to J1 (~0.00 logMAR) at 1 year and remained stable 
over the next 3 years before tapering slightly to J3 (~0.18 
logMAR) after 5 years, with 74.2% of patients reading J3 
(~0.18 logMAR) or better in the treated eye. The BUNVA 
demonstrated the same pattern, but maintained consistently 
better acuity compared to monocular status, achieving a 
mean of J2 (~0.10 logMAR) after 5 years, with 45.2% 
reading at J1 (~0.00 logMAR) or better.22 This pattern was 
also observed for UIVA in both monocular (0.20 logMAR; 
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remaining similar to preoperative after 5 years) and binocu-
lar (0.10 logMAR after 5 years compared to 0.20 logMAR 
preoperatively) states, with over 50% reading 0.10 logMAR 
or better.22 As observed in previous studies, mean UDVA 
decreased slightly from -0.10 logMAR preoperatively 
before tapering over the next 5 years to 0.10 logMAR in the 
treated eye; however, mean BUDVA remained very good 
(-0.10 logMAR) with over 90% achieving 0.00 logMAR 
or better.22 In this study, acuity in the fellow, untreated eye 
was also measured preoperatively and at 5 years postopera-
tively. A similar decrease in UDVA was also observed. As a 
result, the authors attributed the loss of UDVA in both eyes 
to natural age-related hyperopic shift previously identified 
in the Beaver Dam and Liwan Eye Studies.23,24
In addition to measures of acuity, reading performance 
has also been assessed with the original KAMRA inlay. Dexl 
et al reported significant improvements in reading distance 
(reduced working distance), reading acuity at best working 
distance, and smallest print size in over a 2-year period in 
24 natural emmetropic presbyopes.25 However, although an 
increase in reading speed was also observed, this was not 
statistically significant.25
More recently, Tomita and Waring divided their patient 
cohort (n=277) into three age groups (40–49, 50–59, and 
60–65 years) and performed simultaneous LASIK (to correct 
hyperopia) and KAMRA (ACI7000PDT) implantation to 
investigate the effect of age on safety and clinical outcomes 
over a 1-year period. The mean UNVA and UDVA were 
similar between groups, but the 60–65 years age group exhib-
ited the largest gain in both outcomes at the final follow-up 
visit.26 Although this result was not unexpected, this group 
had lowest reduction in spectacle independence. The authors 
concluded that age should be taken into consideration dur-
ing consultation in order to manage patient expectations 
postoperatively.26
Safety and adverse events
From the longer-term studies previously mentioned, it is 
apparent that UDVA in the treated eye and under binocular 
conditions becomes slightly compromised with the KAMRA 
inlay. However, in order to establish whether this is due to 
uncorrected residual ametropia or otherwise, measures of 
best corrected distance visual acuity (CDVA) have been 
evaluated. In the 3-year follow-up study by Seyeddain et al, 
although CDVA remained stable over time, 28.3% of patients 
lost one line and 3.1% lost two lines of acuity in the treated 
eye. Binocular CDVA was, however, stable and no patient 
lost a line of acuity during the follow-up period.20 No inlays 
had to be explanted, but two had to be recentered after 
6 months due to misalignment and no observable improve-
ment in the near and intermediate acuity; once recentered, 
both patients subsequently achieved a significant improve-
ment in these outcomes.20 One patient developed flap striae 
at 1 month and epithelial ingrowth at the flap interface, but 
were successfully resolved following surgical intervention. 
Of note, however, was the development of iron deposits in 
56.2% of patients within a median interval of 18±9 months 
after implantation. Although these deposits were not asso-
ciated with visual or refractive outcomes, corneal topogra-
phy revealed very small areas of flattening overlying the 
deposits.20 Corneal endothelial cell density decreased slightly 
(5.73%) after 6 months, but further significant loss was not 
observed thereafter.20 The most common patient-reported 
symptoms at the final study visit (3 years) were night vision 
problems (40.6% mild, 6.3% moderate, and 15.6% severe 
cases) and halos (34.4%, 25.0%, and 3.1%). Although dry-
ness and glare were also reported, most cases were mild or 
moderate in nature.20
In the 4-year follow-up study, 27% of patients lost more 
than one line of CDVA, but mean CDVA did not change 
significantly from baseline (0.00 logMAR) to the final study 
visit (0.00 logMAR) in the treated eye.21 Four patients had 
the inlay explanted: one at 6 weeks postimplantation due 
to the detection of a buttonhole flap, two at 3 months due 
to large refractive shifts (-2.00 D and +3.00 D), and one at 
17 months due to shallow implantation. All four of these 
patients were, however, successfully treated and no loss of 
monocular or binocular CDVA was observed.21 Compli-
cations reported included dry eye (n=4 treated eyes) and 
epithelial ingrowth (n=5) related to LASIK, but it is not 
clear how the authors differentiated the cause between pre-
vious LASIK procedure and that of KAMRA implantation. 
In the 5-year follow-up study by Dexl et al, mean CDVA 
remained stable at -0.10 logMAR for the first 3 years 
before reducing to 0.00 logMAR after 5 years in the treated 
eye, with 45.2% of patients losing one line and 22.6% los-
ing two or more lines.22 A similar pattern emerged under 
binocular conditions, where mean CDVA reduced slightly 
from -0.20 logMAR preoperatively to -0.10 logMAR after 
5 years, with 51.6% losing one line and 16.1% losing two or 
more lines.22 As observed in the study by Seyeddain et al (old 
inlay design ACI7000), iron deposits developed in 56.3% 
of treated eyes at the 3-year follow-up and were associated 
with overlying corneal flattening; however, no further cases 
were observed for the remaining study period.20,22 The inlay 
was explanted from only one eye at the 36-month follow-up 
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due to a hyperopic shift causing dissatisfaction with near 
and distance vision.
With the current inlay, Tomita et al reported no significant 
change in CDVA from baseline to 6 months postoperatively, 
although 14% of eyes lost one line of acuity in the treated 
eye. Despite this, all patients had monocular CDVA of 0.00 
logMAR or better.17 Visual symptoms were also evaluated, 
albeit using a nonvalidated scale (0= no symptoms, 7= very 
heavy symptoms); here, dryness, glare, halo, and night vision 
disturbances increased significantly, but were considered 
mild by the study authors.17 All patients were post-LASIK 
and therefore may be predisposed to such symptoms, which 
are typically associated with laser refractive procedures, but 
these symptoms should not be discounted, particularly when 
gaining consent for surgery.17,27 Similar results were also 
found by Seyeddain et al, where CDVA reduced by a mean 
of 2.5 letters from -0.10 logMAR to 0.00 logMAR in the 
treated eye, with 16.7% of patients losing one line of acuity 
at the last follow-up (2 years); however, all of these patients 
achieved 0.00 logMAR.18 No implants had to be recentered 
or explanted, and no ocular inflammation was observed dur-
ing the study period.18 Adverse events included epithelial 
ingrowth at the pocket entrance at 1 month in one patient, 
epithelial iron deposits near the inlay margin at 18 months 
in one patient, while several others (number not reported) 
developed a thin hazy appearance at the outer and or inner 
rim of the inlay; however, they did not require treatment and 
were not associated with any visual or refractive outcomes.18 
Further, endothelial cell count (ECC) and central corneal 
thickness (CCT) were not affected over the 2-year follow-up 
period.18 In another study of 24 emmetropic presbyopes who 
underwent monocular (nondominant) implantation, despite 
16.7% losing one line and 4.1% losing two lines of CDVA 
in the treated eye at the final (2-year) follow-up, over 95% 
achieved CDVA of 0.00 logMAR and binocular CDVA 
(-0.10 logMAR) remained stable over the entire study 
period.28 No deposits were observed in or on the cornea, ECC 
and CCT were unaffected, and no patient required the inlay 
to be recentered or explanted.28 Only one patient experienced 
epithelial ingrowth at the pocket entrance after 1 month but 
remained stable and required no intervention.28
Confocal microscopy studies describing the corneal 
appearance with the implant in situ and postexplantation have 
also been performed. Abboud et al found that the implant 
changed the normal structure of the cornea (decreased kera-
tocyte density in the anterior stroma, loss of subbasal nerve 
plexus), but this did not result in visual complications.29 
However, keratocyte activation, also observed in typical 
laser refractive surgery procedures, was observed and this 
was significantly correlated with reduced UNVA, corrected 
near visual acuity, and CDVA.29 Thus, using lower laser 
energy, creating a thicker flap, and applying intensive steroid 
therapy postoperatively are suggested as key for good visual 
outcomes and healing response.29
Discussion
With both the original and current designs of the KAMRA 
implant, the clinical studies have clearly demonstrated sig-
nificant improvements in both near and intermediate visual 
acuity with a minimal impact on distance vision following 
monocular implantation in the nondominant eye of presby-
opes. Although longer-term studies for the current design 
are not yet reported, it is likely that the reduced incidence 
of loss of UDVA and CDVA is a result of improved surgi-
cal technique and implant design.27 The ACI7000 inlay was 
implanted under a corneal flap 170–180 µm deep using a 
microkeratome or femtosecond laser,20–22 whereas the thin-
ner ACI7000PDT inlay is implanted at least 220 µm deep 
in a pocket created with a femtosecond laser, thus the latter 
is less likely to affect corneal topography and subsequent 
visual acuity.18 Not only does the pocket technique allow 
for better centration, it also requires a smaller incision such 
that fewer corneal nerves are cut and therefore reduces the 
likelihood of postoperative dry eye typically associated with 
laser refractive procedures.13,30 Using femtosecond laser 
over mechanical microkeratome to create corneal flaps or 
pockets has been shown to provide lower incidence of post-
operative dry eye, faster visual recovery, better UDVA, and 
more predictable incision depths.18,30,31 Although both inlay 
designs are microperforated to allow water and nutritional 
flow, ACI7000PDT is thinner (6 µm vs 10 µm) and has more 
holes (8,400 vs 1,600), so is less likely to induce corneal thin-
ning and epithelial decompensation.13,32 Indeed, only one in 
20 patients developed epithelial iron deposits with the new 
design compared to over 56% with the ACI7000 inlay.18,20 
However, in either case, these deposits neither interfered with 
vision nor were they associated with refractive outcomes.18
In cases where the inlays were explanted, all resolved 
without sequelae and without significant impact on distance 
vision;2 indeed, Alio et al reported that the KAMRA inlay is 
safe to remove and removal has minimal impact on corneal 
topography and aberrometry during and after recovery if 
explanted before 6 months.33 Thereafter, the changes in cor-
neal topography may remain permanent.33 Despite decentra-
tion as little as 0.5 mm significantly affecting retinal image 
quality, recentration can be performed easily with subsequent 
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improvements in near and distance acuity.14,20 Another major 
advantage of this surgery is that it is additive such that 
where the KAMRA inlays are removed, future options for 
presbyopia correction, including corneal approaches, are still 
available to the patient.32
Given that the inlay relies upon the pinhole effect to 
achieve improvement in near vision, the effect of pupil size 
on clinical outcome has been investigated, as pupil size 
is well known to influence optical image quality based on 
the amount of visual aberrations that pass in the eye after 
refractive surgery.34–36 An optical simulation of the KAMRA 
implant has shown that for combinations of pupil sizes and 
field angles, image brightness on the retina may be attenu-
ated up to 60% due to its central position in front of the pupil 
and opaque nature, and it is predicted that this vignetting 
effect may lead to a clinically relevant reduction in contrast 
sensitivity.37 However, in a study of 584 actual KAMRA inlay 
treated eyes (584 patients), Tomita et al report that pupil size 
had no impact on visual acuity after implantation. There was 
no statistically significant difference between uncorrected 
and distance-corrected near visual acuity for both mesopic 
and photopic size groups.38 One study has reported a statisti-
cally significant reduction in contrast sensitivity in eyes with 
KAMRA inlays compared to preoperative measurements after 
24 months in photopic and mesopic conditions, but these were 
found at higher spatial frequencies and the measures were 
within the range of the normal population.18 Another paper 
published by Vilupuru et al reported no loss of binocular con-
trast in either photopic or mesopic conditions for a series of 
507 patients implanted monocularly with the KAMRA inlay. 
This same study also compared contrast sensitivity results 
for KAMRA inlay subjects to subjects treated with bilateral 
multifocal or accommodating intraocular lenses. Under all 
conditions, the KAMRA inlay patients demonstrated better 
contrast sensitivity than patients with the tested lenses.39
Conclusion
The KAMRA inlay is a safe and effective clinical procedure 
for the treatment of presbyopia, where significant improve-
ment in near and intermediate visual acuity and function 
has been reported in several large and long-term follow-up 
studies. Although distance visual acuity has been compro-
mised in some patients, the reductions were not clinically 
significant. Iron deposits within the corneal epithelium have 
been observed, but these are not considered to affect vision, 
and the incidence has reduced with improvements in surgical 
methods and the inlay design itself. Further studies with the 
latest KAMRA inlay are required to establish the longer-term 
safety and clinical stability of visual acuity.
Disclosure
The authors report no conflicts of interest in this work. The 
figures were supplied courtesy of AcuFocus Inc. (Irvine, 
CA, USA).
References
 1. Pau H, Kranz J. The increasing sclerosis of the human lens with age 
and its relevance to accommodation and presbyopia. Graefes Arch Clin 
Exp Ophthalmol. 1991;229(3):294–296.
 2. Glasser A, Campbell MC. Presbyopia and the optical changes in the 
human crystalline lens with age. Vision Res. 1998;38(2):209–229.
 3. Heys KR, Truscott RJ. The stiffness of human cataract lenses is a 
function of both age and the type of cataract. Exp Eye Res. 2008;86(4): 
701–703.
 4. Strenk SA, Semmlow JL, Strenk LM, Munoz P, Gronlund-Jacob J, 
DeMarco JK. Age-related changes in human ciliary muscle and lens: 
a magnetic resonance imaging study. Invest Ophthalmol Vis Sci. 1999; 
40(6):1162–1169.
 5. Strenk SA, Strenk LM, Semmlow JL. High resolution MRI study of 
circumlental space in the aging eye. J Ref Surg. 2000;16(5):659–660.
 6. Strenk SA, Strenk LM, Koretz JF. The mechanism of presbyopia. Prog 
Retin Eye Res. 2005;24(3):379–393.
 7. Patel I, West SK. Presbyopia: prevalence, impact, and interventions. 
Community Eye Health. 2007;20(63):40–41.
 8. Limnopoulou AN, Bouzoukis DI, Kymionis GD, et al. Visual outcomes 
and safety of a refractive corneal inlay for presbyopia using femtosecond 
laser. J Refract Surg. 2013;29(1):12–18.
 9. Chayet A, Garza EB. Combined hydrogel inlay and laser in situ 
keratomileusis to compensate for presbyopia in hyperopic patients: 
one-year safety and efficacy. J Cataract Refract Surg. 2013;39(11): 
1713–1721.
 10. Garza EB, Gomez S, Chayet A, Dishler J. One-year safety and efficacy 
results of a hydrogel inlay to improve near vision in patients with 
emmetropic presbyopia. J Refract Surg. 2013;29(3):166–172.
 11. Tabernero J, Schwarz C, Fernández EJ, Artal P. Binocular visual simu-
lation of a corneal inlay to increase depth of focus. Invest Ophthalmol 
Vis Sci. 2011;52(8):5273–5277.
 12. Lindstrom RL, MacRae SM, Pepose JS, Hoopes PC Sr. Corneal 
inlays for presbyopia correction. Curr Opin Ophthalmol. 2013;24(4): 
281–287.
 13. Dexl AK, Seyeddain O, Riha W, et al. One-year visual outcomes and 
patient satisfaction after surgical correction of presbyopia with an 
intracorneal inlay of a new design. J Cataract Refract Surg. 2012;38(2): 
262–269.
 14. Tomita M, Kanamori T, Waring GO, et al. Simultaneous corneal inlay 
implantation and laser in situ keratomileusis for presbyopia in patients 
with hyperopia, myopia, or emmetropia: six-month results. J Cataract 
Refract Surg. 2012;38(3):495–506.
 15. Huseynova T, Kanamori T, Waring IV GO, Tomita M. Small-aperture 
corneal inlay in presbyopic patients with prior phakic intraocular lens 
implantation surgery: 3-month results. Clin Ophthalmol. 2013;7: 
1683–1686.
 16. Tabernero J, Artal P. Optical modelling of a corneal inlay in real eyes 
to increase depth of focus: optimum centration and residual defocus. 
J Cataract Refract Surg. 2012;38(2):270–277.
 17. Tomita M, Kanamori T, Waring GO, Nakamura T, Yukawa S. Small-
aperture corneal inlay implantation to treat presbyopia after laser in situ 
keratomileusis. J Cataract Refract Surg. 2013;39(6):898–905.
 18. Seyeddain O, Bachernegg A, Riha W, et al. Femtosecond laser-assisted 
small-aperture corneal inlay implantation for corneal compensation of 
presbyopia: two-year follow-up. J Cataract Refract Surg. 2013;39(2): 
234–241.
 19. Seyeddain O, Riha W, Hohensinn M, Nix G, Dexl AK, Grabner G. 
Refractive surgical correction of presbyopia with the AcuFocus small 
aperture corneal inlay: two-year follow-up. J Refract Surg. 2010;26(10): 
707–715.
Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
919
KAMRA inlay utility
 20. Seyeddain O, Hohensinn M, Riha W, et al. Small-aperture corneal inlay 
for the correction of presbyopia: 3-year follow-up. J Cataract Refract 
Surg. 2012;38(1):35–45.
 21. Yılmaz ÖF, Alagöz N, Pekel G. Intracorneal inlay to correct presbyopia: 
long-term results. J Cataract Refract Surg. 2011;37(7):1275–1281.
 22. Dexl AK, Jell G, Strohmaier C. Long-term outcomes after monocular 
corneal inlay implantation for the surgical compensation of presbyopia. 
J Cataract Refract Surg. 2015;41(3):566–575.
 23. Lee KE, Klein BE, Klein R, Wong TY. Changes in refraction over 
10 years in an adult population: the Beaver Dam Eye study. Invest 
Ophthalmol Vis Sci. 2002;43(8):2566–2571.
 24. He M, Huang W, Li Y, Zheng Y, Yin Q, Foster PJ. Refractive error 
and biometry in older Chinese adults: the Liwan eye study. Invest 
Ophthalmol Vis Sci. 2009;50(11):5130–5136.
 25. Dexl AK, Seyeddain O, Riha W, Hohensinn M, Hitzl W, Grabner G. 
Reading performance after implantation of a small-aperture corneal 
inlay for the surgical correction of presbyopia: two-year follow-up. 
J Cataract Refract Surg. 2011;37(3):525–531.
 26. Tomita M, Waring GO. One-year results of simultaneous laser in situ ker-
atomileusis and small-aperture corneal inlay implantation for hyperopic 
presbyopia: comparison by age. J Cataract Refract Surg. 2015;41(1): 
152–161.
 27. Melki SA, Azar DT. LASIK complications: etiology, management, and 
prevention. Surv Ophthalmol. 2011;46(2):95–116.
 28. Dexl AK, Seyeddain O, Riha W. Reading performance and patient satis-
faction after corneal inlay implantation for presbyopia correction: two-
year follow-up. J Cataract Refract Surg. 2012;38(10):1808–1816.
 29. Abboud A, Javaloy J, Alió JL. Confocal microscopy evaluation of the 
corneal response following AcuFocus KAMRA inlay implantation. 
J Refract Surg. 2014;30(3):172–178.
 30. Salomão MQ, Ambrósio R, Wilson SE. Dry eye associated with laser 
in situ keratomileusis: mechanical microkeratome versus femtosecond 
laser. J Cataract Refract Surg. 2009;35(10):1756–1760.
 31. Kezirian GM, Stonecipher KG. Comparison of the IntraLase femto-
second laser and mechanical keratomes for laser in situ keratomileusis. 
J Cataract Refract Surg. 2004;30(4):804–811.
 32. Arlt EM, Krall EM, Moussa S, Grabner G, Dexl AK. Implantable 
inlay devices for presbyopia: the evidence to date. Clin Ophthalmol. 
2015;9:129–137.
 33. Alió JL, Abbouda A, Huseynli S, Knorz MC, Durrie DS. Removability 
of a small aperture intracorneal inlay for presbyopia correction. J Refract 
Surg. 2013;29(8):550–556.
 34. Martinez CE, Applegate RA, Klyce SD, McDonald MB, Medina JP, 
Howland HC. Effect of pupillary dilation on corneal optical aberrations 
after photorefractive keratectomy. Arch Ophthalmol. 1998;116(8): 
1053–1062.
 35. Miller JM, Anwaruddin R, Straub J, Schwiegerling J. Higher order 
aberrations in normal, dilated, intraocular lens, and laser in situ ker-
atomileusis corneas. J Refract Surg. 2002;18(5):S579–S583.
 36. Wang B, Ciuffreda KJ. Depth-of-focus of the human eye: theory and 
clinical implications. Surv Ophthalmol. 2006;51(1):75–85.
 37. Langenbucher A, Goebels S, Szentmáry N, Seitz B, Eppig T. Vignett-
ing and field of view with the KAMRA corneal inlay. Biomed Res Int. 
2013;2013:154593.
 38. Tomita M, Kanamori T, Waring GO, Huseynova T. Retrospective 
evaluation of the influence of pupil size on visual acuity after KAMRA 
inlay implantation. J Refract Surg. 2014;30(7):448–453.
 39. Vilupuru S, Lin L, Pepose JS. Comparison of contrast sensitivity and through 
focus in small aperture inlay, accommodating intraocular lens, or multifocal 
intraocular lens subjects. Am J Ophthalmol. 2015;160(1):150–162.
